Skip to main content
All lobbying filings

ARDELYX, INC.

Lobbying for ARDELYX, INC.

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 18, 2025
Expenses
$540,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments.

Medicaid rebate, most favored nation drug pricing. Increase Access to Innovation for People with Kidney Failure. Support Medicare Part D access to phosphorus-lowering medications.

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem